Ibuprofen And Pseudoephedrine Hydrochloride Tablet, Sugar Coated
RxNorm Crosswalk NDC 59779-430

View RxNorm Concepts, RxCUIs, and Term Type mappings for this NDC

RxNorm Mapping Clinical Concepts

This drug is included in the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States.

The product Ibuprofen And Pseudoephedrine Hydrochloride (NDC 59779-430) is cross-mapped to the RxNorm terminology system to ensure clinical interoperability. This formulation is linked to a unique clinical concept (RxCUI 1299021). By anchoring Cvs Pharmacy's product data to these standardized identifiers, healthcare systems can maintain accurate medication records, safely automate e-prescribing, and streamline pharmacy workflows.

The following clinical concept cards detail the semantic term types (TTY), prescribable names, and synonymous clinical strings as defined by the National Library of Medicine (NLM).

SCDPrescribable
Featured Concept

ibuprofen 200 MG / pseudoephedrine hydrochloride 30 MG Oral Tablet
(RxCUI 1299021)

Semantic Clinical Drug

Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.

Understanding RxNorm Mapping for Ibuprofen And Pseudoephedrine Hydrochloride

RxNorm is a normalized naming system developed by the National Library of Medicine (NLM) to bridge the gap between different drug terminologies. By mapping NDC 59779-430 to RxCUI 1299021, this page provides the standardized "source of truth" required for hospital systems, e-prescribing software, and pharmacy benefit managers (PBMs) to communicate without errors.

Term Type (TTY) Legend for This Page

The clinical cards above utilize specific Term Types (TTY) to define the granularity of the drug concept:

  • PSN Prescribable Name: The standardized name preferred by electronic prescribing (eRx) applications for display.
  • SCD Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.

* Please review the full disclaimer at the bottom of this page.